Life sciences firm NanoVision Diagnostics, spun out from the University of Pittsburgh last year, raises $1.5m for early stage cancer detection.
NanoVision Diagnostics, a life sciences spin-out from the University of Pittsburgh, has raised $1.5m towards a planned £3.25m round, according to a SEC filing. The Pittsburgh-based firm, which spun out from the university last year, is developing a diagnostics system for identifying early-stage cancer. NanoVision uses what it describes as optical biomarkers to detect cancer,…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
